Odyssey Health, Inc. filings document a Nevada medical technology issuer with OTC-traded common stock and a portfolio centered on medical devices and life-saving medical solutions. Its Form 8-K reports cover material definitive agreements, maintenance-service arrangements, financing facilities, promissory notes, convertible notes, warrants, maturity extensions and related capital-structure disclosures.
The company’s registration and periodic disclosure record also addresses securities offerings, operating and financial results, risk factors, shareholder matters, clinical or regulatory disclosures, and governance matters. These filings provide the formal record for Odyssey Health’s public-company obligations, its financing activity, and changes affecting its medical technology asset base.
Odyssey Health, Inc. reported no revenue for the year ended July 31, 2026 and a net loss of $5,729,693, compared with a net loss of $1,742,691 for the year ended July 31, 2025. Net cash used in operating activities was $1,046,358.
At July 31, 2026, cash was $122,361, current liabilities were $12,277,546, and the working capital deficit was $12,129,687. Odyssey disclosed substantial doubt about its ability to continue as a going concern. Convertible notes totaled $4,876,282 in principal, plus accrued interest, including $3,835,282 owed to Mast Hill. Odyssey said it lacked funds to repay the notes at their extended January 31, 2027 maturity. An October 23, 2026 amendment extended all four Mast Hill note maturities and granted limited, one-time waivers for specified defaults.
No products are authorized for commercial distribution. Odyssey says Save-A-Life will be prioritized for further development, while CardioMap development will remain suspended in the near term. Both require FDA clearance or approval before U.S. sales.
Odyssey Health, Inc. (ODYY) entered two amendments on September 29, 2026, extending the maturity dates of notes with LGH Investments, LLC and Peter J. D’Arruda to January 31, 2027. The LGH amendment is No. 13 to a convertible promissory note dated April 5, 2021. The other is Amendment No. 1 to a promissory note with accredited investor Peter J. D’Arruda, dated October 1, 2025. Odyssey Health stated that all other terms and conditions remain the same.
Odyssey Health, Inc. reported a small quarterly profit but remains in a fragile financial position. For the quarter ended April 30, 2026, the company generated net income of $765,890, mainly from a $1.5M non‑cash gain on the change in fair value of derivative liabilities and an $85,369 gain from forgiven payables, while operations still lost money.
The business recorded no revenue for the nine months and focuses on developing medical devices such as CardioMap and the Save‑A‑Life choking rescue device. For the nine months ended April 30, 2026, it posted a net loss of $3.3M and an accumulated deficit of $66.1M.
Liquidity is tight: cash was only $297,806 with current liabilities of $10.1M, resulting in a working capital deficit of $9.75M. Management states there is substantial doubt about the company’s ability to continue as a going concern and is relying on high‑cost convertible debt, complex derivative structures, and related warrants from investors such as Mast Hill and LGH to fund operations.
Odyssey Health, Inc. disclosed that it entered into Amendment No. 12 with LGH Investments, LLC to its existing convertible promissory note. The amendment, effective as of April 30, 2026, extends the note’s maturity date to September 30, 2026. All other terms and conditions of the note remain unchanged.
Odyssey Health, Inc. reports that NeuRX Health, Inc. sent a formal letter on May 6, 2026 stating that the definitive agreement between NeuRX and Odyssey dated October 14, 2025, which closed on April 21, 2026, is immediately cancelled.
The letter relates to NeuRX’s sublicensing of Davion Healthcare Plc’s BreastCheck product to Odyssey and refers to issues with required consents and approvals under Davion’s arrangements. Odyssey has filed the NeuRX revocation letter as an exhibit to this report.
Odyssey Health, Inc. closed a definitive sub-license agreement giving its subsidiary, Odyssey Medical Devices, exclusive worldwide marketing and distribution rights to BreastCheck™, a non-invasive at-home breast screening test. BreastCheck™ delivers results in about 15 minutes and is intended as a first-line adjunct to mammography and clinical exams.
The test is registered with regulators in the U.S., European Union, and United Kingdom, supporting an international commercial footprint. Odyssey highlights this agreement as a key step in shifting toward revenue-generating products, with commercial sales of BreastCheck™ anticipated in the second half of the year and a focus on recurring revenue from repeat screening use.
Odyssey Health, Inc. reported a larger loss and ongoing financial strain for the quarter ended January 31, 2026. The company generated no revenue and posted a net loss of $3,601,623 for the quarter and $4,085,070 for the six-month period, significantly higher than a year earlier.
Cash improved to $616,327, but current assets of $721,304 were far below current liabilities of $11,317,123, resulting in a working capital deficit of $10,595,819. Total stockholders’ deficit widened to $10,595,819, with an accumulated deficit of $66,830,907.
Losses were driven mainly by financing costs of $2,572,655, interest expense of $412,429, and a $424,348 loss from changes in derivative liabilities tied to recent Mast Hill financing arrangements. Derivative liabilities reached $3,936,166, reflecting highly structured convertible debt and warrants.
Management disclosed substantial doubt about Odyssey’s ability to continue as a going concern, citing recurring losses, negative cash flows and dependence on additional capital. The company continues to develop its CardioMap and Save-A-Life devices and entered a new BreastCheck® sublicense, but has not yet obtained regulatory clearance or begun product sales.
Odyssey Health, Inc. entered into several note amendments to push out upcoming debt maturities. On January 30, 2026, the company signed four Amendment No. 12 agreements with two directors and two officers to extend the maturity of their Convertible Promissory Notes to January 31, 2027.
On the same date, Odyssey amended a Convertible Promissory Note with LGH Investments, LLC (Amendment No. 11) to extend its maturity to April 30, 2026. It also amended a Promissory Note with accredited investor Jonathan Lutz (Amendment No. 5) to extend maturity to January 31, 2027, and a Promissory Note with accredited investor Peter J. D’Arruda (Amendment No. 2, entered February 2, 2026 and effective January 31, 2026) to the same January 31, 2027 date. Forms of these amendments are filed as exhibits.
Odyssey Health Inc. is registering 18,000,000 shares of common stock for resale by Mast Hill Fund, L.P. These shares relate to the conversion of a $2,262,000 Maintenance Agreement convertible promissory note, a $500,000 purchase agreement note, and the exercise of a warrant for 1,538,461 shares, all convertible or exercisable at a 15% discount to the lowest volume weighted average price over the prior 10 trading days. Odyssey will not receive proceeds from Mast Hill Fund’s resale of these shares, but may receive up to $25,000,000 in gross proceeds over time from selling common stock to Mast Hill Fund under a Securities Purchase Agreement, plus warrant exercise proceeds. As of December 17, 2025, Odyssey had 99,853,763 common shares outstanding, and if all 18,000,000 registered shares were issued they would represent about 15% of the then-outstanding stock. The company warns that these arrangements may cause substantial dilution and that large or anticipated resales could put pressure on its OTCQB-traded share price.